Greater Asia News
SK pharmteco doubles viral vector production capacity in Europe
SEOUL, South Korea, June 22, 2023 /PRNewswire/ -- SK pharmteco, SK Inc.'s contract development manufacturing organization (CDMO) for pharmaceuticals, successfully completed its second facility for Cell and Gene Therapies (C>) manufacturing in Europe.
SK bioscience COVID-19 Vaccine Granted Emergency Use Listing by the World Health Organization
SEONGNAM, South Korea, June 19, 2023 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced the company has received the WHO Emergency Use Listing (EUL) of its COVID-19 vaccine, SKYCovione.
Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda(TSE:4502/NYSE:TAK) today announced full results from the pivotal Phase 3 ADVANCE-CIDP 1 clinical trial investigating HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] as maintenance therapy in adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
Jadeite Medicines Receives Orphan Drug Designation for Odevixibat in Progressive Familial Intrahepatic Cholestasis (PFIC) from the Ministry of Health, Labour and Welfare of Japan and will also initiate Phase 3 Trial of Odevixibat in PFIC in Japan
TOKYO, June 20, 2023 /PRNewswire/ -- Jadeite Medicines Inc., (Jadeite Medicines) a clinical stage biopharmaceutical company headquartered in Tokyo, Japan (President & CEO, Eiichi Takahashi) has received Orphan Drug Designation for odevixibat for the expected indication of PFIC from the Ministry of Health, Labour and Welfare (MHLW) of Japan.
Tessa Therapeutics’s ‘Off-the-Shelf’ CAR-T Therapy Shows Promising Results in Early-Stage Study of Hodgkin Lymphoma
SINGAPORE – June 16, 2023 – Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced promising safety and efficacy data from a study of its off-the-shelf CD30.CAR EBVST therapy (TT11X) in patients with relapsed or refractory (R/R) Hodgkin lymphoma.
GC Genome’s New Study Reveals Link Between Gut Microbiome and High Blood Pressure
YONGIN, South Korea, June 14, 2023 /PRNewswire/ -- GC Genome Corporation, a leading genomic diagnostics company, announced the publication of a study in Frontiers in Microbiomes.
Gencurix Obtains Approval for Companion Diagnostic of Digital PCR-based EGFR Mutation Test
SEOUL, South Korea, June 13, 2023 /PRNewswire/ -- Gencurix, a leading cancer molecular diagnostics company, has obtained approval from the Korean Ministry of Food and Drug Safety for its Droplex EGFR Mutation Test v2.
Springer Nature to Join Seegene’s OneSystem™ Business as Strategic Partner
SEOUL, South Korea, June 15, 2023 /PRNewswire/ -- Seegene Inc. (KQ096530), a leading South Korean company providing a total solution for PCR molecular diagnostics, announced today that it has signed a strategic partnership agreement with Springer Nature to expand its OneSystem™ Business.
OliX Pharmaceuticals Administers First Patient in Phase 1 Clinical Study of RNAi Therapeutic OLX72021 for Androgenic Alopecia
SUWON, South Korea--(BUSINESS WIRE)--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced today that the first patient has been administered on June 5, in a Phase 1 clinical trial, evaluating OLX72021, an investigational RNAi therapeutic intended for the treatment of androgenic alopecia, also known as male-pattern baldness.
Siemens to spend $2.2 bln to ramp up global production
SINGAPORE/ZURICH, June 15 (Reuters) - Siemens (SIEGn.DE) will spend 2 billion euros ($2.2 billion) on a new global investment plan, the German engineering group said on Thursday, to make its operations more resilient against supply chain disruptions and geopolitical tensions.
